SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease

被引：34

作者：

Bermudez, LE

Kolonoski, P

Seitz, LE

Petrofsky, M

Reynolds, R

Wu, M

Young, LS

机构：

[1] Oregon State Univ, Coll Vet Med, Dept Biomed Sci, Corvallis, OR 97331 USA

[2] Calif Pacific Med Ctr, Inst Res, Kuzell Inst, San Francisco, CA USA

[3] Oregon State Univ, Dept Microbiol, Coll Sci, Corvallis, OR 97331 USA

[4] So Res Inst, Birmingham, AL 35255 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 09期

关键词：

D O I：

10.1128/AAC.48.9.3556-3558.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were better than mefloquine alone.

引用

收藏

页码：3556 / 3558

页数：3

相关论文

共 15 条

[1] Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice [J].

Bermudez, LE ;

Reynolds, R ;

Kolonoski, P ;

Aralar, P ;

Inderlied, CB ;

Young, LS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2685-2687

[2] Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease [J].

Bermudez, LE ;

Kolonoski, P ;

Petrofsky, M ;

Wu, M ;

Inderlied, CB ;

Young, LS .

JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (12) :1977-1980

[3] Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium [J].

Bermudez, LE ;

Inderlied, CB ;

Kolonoski, P ;

Petrofsky, M ;

Aralar, P ;

Wu, M ;

Young, LS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :217-222

[4] Mefloquine is active in vitro and in vivo against Mycobacterium avium complex [J].

Bermudez, LE ;

Kolonoski, P ;

Wu, M ;

Aralar, PA ;

Inderlied, CB ;

Young, LS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1870-1874

[5] CLARITHROMYCIN THERAPY FOR BACTEREMIC MYCOBACTERIUM-AVIUM COMPLEX DISEASE - A RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY IN PATIENTS WITH AIDS [J].

CHAISSON, RE ;

BENSON, CA ;

DUBE, MP ;

HEIFETS, LB ;

KORVICK, JA ;

ELKIN, S ;

SMITH, T ;

CRAFT, JC ;

SATTLER, FR ;

STOOL, EW ;

MACGREGOR, RR ;

BUEHNER, T ;

WU, AW ;

BARNES, GL ;

BECKER, R ;

URBANSKI, P ;

RICHARDSON, W ;

HAFNER, R ;

DIXON, D ;

FEIGAL, DW ;

DELLERSON, M ;

GUPTA, S ;

HENRY, D ;

SCHLAGER, S .

ANNALS OF INTERNAL MEDICINE, 1994, 121 (12) :905-911

[6]

COUNCIL EAB, 1963, TUBERCLE, V44, P301

[7] Side effects of mefloquine prophylaxis for malaria: An independent randomized controlled trial [J].

Croft, AMJ ;

Clayton, TC ;

World, MJ .

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1997, 91 (02) :199-203

[8] INVITRO AND INVIVO ACTIVITIES OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM [J].

FERNANDES, PB ;

HARDY, DJ ;

MCDANIEL, D ;

HANSON, CW ;

SWANSON, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1531-1534

[9] INVITRO AND INVIVO ACTIVITY OF AZITHROMYCIN (CP-62,993) AGAINST THE MYCOBACTERIUM-AVIUM COMPLEX [J].

INDERLIED, CB ;

KOLONOSKI, PT ;

WU, M ;

YOUNG, LS .

JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (05) :994-997

[10] THE MYCOBACTERIUM-AVIUM COMPLEX [J].

INDERLIED, CB ;

KEMPER, CA ;

BERMUDEZ, LEM .

CLINICAL MICROBIOLOGY REVIEWS, 1993, 6 (03) :266-310